Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
6.40
+0.05 (0.79%)
At close: Aug 13, 2025, 4:00 PM
6.16
-0.24 (-3.75%)
Pre-market: Aug 14, 2025, 9:15 AM EDT
Candel Therapeutics Employees
Candel Therapeutics had 38 employees as of December 31, 2024. The number of employees decreased by 4 or -9.52% compared to the previous year.
Employees
38
Change (1Y)
-4
Growth (1Y)
-9.52%
Revenue / Employee
n/a
Profits / Employee
-$1,041,500
Market Cap
341.27M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 38 | -4 | -9.52% |
Dec 31, 2023 | 42 | -34 | -44.74% |
Dec 31, 2022 | 76 | 11 | 16.92% |
Dec 31, 2021 | 65 | 24 | 58.54% |
Dec 31, 2020 | 41 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CADL News
- 15 days ago - Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 21 days ago - Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer - GlobeNewsWire
- 5 weeks ago - Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution - GlobeNewsWire
- 7 weeks ago - Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - GlobeNewsWire
- 2 months ago - Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer - GlobeNewsWire
- 2 months ago - Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation - GlobeNewsWire